COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.

التفاصيل البيبلوغرافية
العنوان:	COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.
المؤلفون:	Mazagatos, Clara, Delgado-Sanz, Concepción, Monge, Susana, Pozo, Francisco, Oliva, Jesús, Sandonis, Virginia, Gandarillas, Ana, Quiñones-Rubio, Carmen, Ruiz-Sopeña, Cristina, Gallardo-García, Virtudes, Basile, Luca, Barranco-Boada, María Isabel, Hidalgo-Pardo, Olga, Vazquez-Cancela, Olalla, García-Vázquez, Miriam, Fernández-Sierra, Amelia, Milagro-Beamonte, Ana, Ordobás, María, Martínez-Ochoa, Eva, Fernández-Arribas, Socorro, Lorusso, Nicola, Martínez, Ana, García-Fulgueiras, Ana, Sastre-Palou, Bartolomé, Losada-Castillo, Isabel, Martínez-Cuenca, Silvia, Rodríguez-Del Águila, Mar, Latorre, Miriam, Larrauri, Amparo, SARI surveillance VE group in Spain
سنة النشر:	2022
المجموعة:	Sistema Sanitario Público de Andalucía (SSPA): Repositorio
مصطلحات موضوعية:	COVID-19, COVID-19 vaccine, SARI surveillance, SARS-CoV-2, Spain, test-negative design, vaccine effectiveness, COVID-19 Vaccines, Hospitalization, Humans, Respiratory Tract Infections, Sentinel Surveillance, Vaccine Efficacy
الوصف:	With the emergence of SARS-CoV-2, influenza surveillance systems in Spain were transformed into a new syndromic sentinel surveillance system. The Acute Respiratory Infection Surveillance System (SiVIRA in Spanish) is based on a sentinel network for acute respiratory infection (ARI) surveillance in primary care and a network of sentinel hospitals for severe ARI (SARI) surveillance in hospitals. Using a test-negative design and data from SARI admissions notified to SiVIRA between January 1 and October 3, 2021, we estimated COVID-19 vaccine effectiveness (VE) against hospitalization, by age group, vaccine type, time since vaccination, and SARS-CoV-2 variant. VE was 89% (95% CI: 83-93) against COVID-19 hospitalization overall in persons aged 20 years and older. VE was higher for mRNA vaccines, and lower for those aged 80 years and older, with a decrease in protection beyond 3 months of completing vaccination, and a further decrease after 5 months. We found no differences between periods with circulation of Alpha or Delta SARS-CoV-2 variants, although variant-specific VE was slightly higher against Alpha. The SiVIRA sentinel hospital surveillance network in Spain was able to describe clinical and epidemiological characteristics of SARI hospitalizations and provide estimates of COVID-19 VE in the population under surveillance. Our estimates add to evidence of high effectiveness of mRNA vaccines against severe COVID-19 and waning of protection with time since vaccination in those aged 80 or older. No substantial differences were observed between SARS-CoV-2 variants (Alpha vs. Delta).
نوع الوثيقة:	article in journal/newspaper
وصف الملف:	application/pdf
اللغة:	English
تدمد:	1750-2659
Relation:	http://hdl.handle.net/10668/19976; PMC9350393; https://docusalut.com/bitstream/20.500.13003/18274/1/influenza_other_respi_viruses_2022-02-17.pdf; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350393/pdf
DOI:	10.1111/irv.13026
الاتاحة:	http://hdl.handle.net/10668/19976 https://doi.org/10.1111/irv.13026 https://docusalut.com/bitstream/20.500.13003/18274/1/influenza_other_respi_viruses_2022-02-17.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350393/pdf
Rights:	Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0/ ; open access
رقم الانضمام:	edsbas.189499C5
قاعدة البيانات:	BASE

View record in BASE

Full Text Finder

الوصف
تدمد:	17502659
DOI:	10.1111/irv.13026